{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:14:12Z","timestamp":1783678452784,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":116,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.100992","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:00:51Z","timestamp":1777942851000},"page":"100992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nonlinear Association Between Metabolic Syndrome Severity and Advanced Fibrosis in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-2438","authenticated-orcid":false,"given":"Mohamed I.","family":"Elsaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1947-6048","authenticated-orcid":false,"given":"Yesung","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-3214","authenticated-orcid":false,"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-8299","authenticated-orcid":false,"given":"Electra D.","family":"Paskett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-6514","authenticated-orcid":false,"given":"Khalid","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-5783","authenticated-orcid":false,"given":"Vinod K.","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.gastha.2026.100992_bib1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.gastha.2026.100992_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cld.2015.10.002","article-title":"The metabolic syndrome and its influence on nonalcoholic steatohepatitis","volume":"20","author":"Kanwar","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.gastha.2026.100992_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2174\/1381612826666200303114934","article-title":"Epidemiology of non-alcoholic fatty liver disease in North America","volume":"26","author":"Arshad","year":"2020","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/apt.17158","article-title":"The epidemiologic burden of non-alcoholic fatty liver disease across the world","volume":"56","author":"Henry","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib7","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.crd.0000380842.14048.7e","article-title":"Diagnosis and management of the metabolic syndrome. An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary","volume":"13","author":"Grundy","year":"2005","journal-title":"Cardiol Rev"},{"issue":"5","key":"10.1016\/j.gastha.2026.100992_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100727","article-title":"The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study","volume":"27","author":"Hamid","year":"2022","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2026.100992_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cld.2017.08.013","article-title":"Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"22","author":"Gawrieh","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.gastha.2026.100992_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12072-023-10550-9","article-title":"Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy","volume":"17","author":"Chan","year":"2023","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib14","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology"},{"issue":"39","key":"10.1016\/j.gastha.2026.100992_bib16","doi-asserted-by":"crossref","first-page":"14185","DOI":"10.3748\/wjg.v20.i39.14185","article-title":"Nonalcoholic fatty liver disease and aging: epidemiology to management","volume":"20","author":"Bertolotti","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.100992_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2862173","article-title":"The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background","volume":"2016","author":"Yu","year":"2016","journal-title":"Gastroenterol Res Pract"},{"issue":"5\u20136","key":"10.1016\/j.gastha.2026.100992_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"Huang","year":"2009","journal-title":"Dis Models Mech"},{"issue":"2","key":"10.1016\/j.gastha.2026.100992_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cld.2015.10.010","article-title":"Progression and natural history of nonalcoholic fatty liver disease in adults","volume":"20","author":"Marengo","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gastha.2026.100992_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.metabol.2013.10.006","article-title":"An examination of sex and racial\/ethnic differences in the metabolic syndrome among adults: a confirmatory factor analysis and a resulting continuous severity score","volume":"63","author":"Gurka","year":"2014","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.gastha.2026.100992_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","article-title":"The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population","volume":"51","author":"Jinjuvadia","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastha.2026.100992_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/DMSO.S101624","article-title":"Clinical utility of metabolic syndrome severity scores: considerations for practitioners","volume":"10","author":"DeBoer","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13098-018-0344-3","article-title":"Assessing the added predictive ability of a metabolic syndrome severity score in predicting incident cardiovascular disease and type 2 diabetes: the Atherosclerosis Risk in Communities Study and Jackson Heart Study","volume":"10","author":"Guo","year":"2018","journal-title":"Diabetol Metab Syndr"},{"issue":"7","key":"10.1016\/j.gastha.2026.100992_bib28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00125-017-4267-6","article-title":"Independent associations between a metabolic syndrome severity score and future diabetes by sex and race: the Atherosclerosis Risk in Communities Study and Jackson Heart Study","volume":"60","author":"Gurka","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12933-017-0647-y","article-title":"Metabolic syndrome severity is significantly associated with future coronary heart disease in type 2 diabetes","volume":"17","author":"Gurka","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.gastha.2022.02.002","article-title":"Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease","volume":"1","author":"Elsaid","year":"2022","journal-title":"Gastro Hep Adv"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299836","article-title":"The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"19","author":"Elsaid","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.gastha.2026.100992_bib32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2026.100992_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nutres.2020.12.023","article-title":"Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis","volume":"88","author":"DeBoer","year":"2021","journal-title":"Nutr Res"},{"issue":"9","key":"10.1016\/j.gastha.2026.100992_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis"},{"issue":"10","key":"10.1016\/j.gastha.2026.100992_bib35","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.gastha.2026.100992_bib36","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.gastha.2026.100992_bib37","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/cells8111419","article-title":"TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis-updated 2019","volume":"8","author":"Dewidar","year":"2019","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib38","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.3892\/mmr.2017.7641","article-title":"PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review)","volume":"16","author":"Ying","year":"2017","journal-title":"Mol Med Rep"},{"issue":"11","key":"10.1016\/j.gastha.2026.100992_bib39","first-page":"1622","article-title":"Gut-liver axis and non-alcoholic fatty liver disease: a vicious circle of dysfunctions orchestrated by the gut microbiome","volume":"11","author":"Pezzino","year":"2022","journal-title":"Biology (Basel)"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101154","article-title":"Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: an updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018","volume":"29","author":"Wang","year":"2024","journal-title":"Ann Hepatol"},{"issue":"7","key":"10.1016\/j.gastha.2026.100992_bib42","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep4.1935","article-title":"Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning","volume":"6","author":"Noureddin","year":"2022","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.gastha.2026.100992_bib43","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10620-022-07707-1","article-title":"Prepandemic prevalence estimates of fatty liver disease and fibrosis defined by liver elastography in the United States","volume":"68","author":"Unalp-Arida","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252164","article-title":"Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: results from NHANES 2017-2018","volume":"16","author":"Zhang","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.gastha.2026.100992_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000249","article-title":"Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting","volume":"7","author":"Park","year":"2023","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib46","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/apt.18101","article-title":"Global epidemiology of alcohol-associated liver disease in adolescents and young adults","volume":"60","author":"Danpanichkul","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gastha.2026.100992_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12072-018-09926-z","article-title":"Race\/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005\u20132016","volume":"13","author":"Kim","year":"2019","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.gastha.2026.100992_bib48","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/jgh.14734","article-title":"Type 2 diabetes mellitus: a risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease","volume":"34","author":"Tada","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib49","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2026.100992_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2001.25540","article-title":"Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese","volume":"121","author":"Dixon","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gastha.2026.100992_bib51","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.gastha.2026.100992_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/joim.13035","article-title":"Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016","volume":"287","author":"Le","year":"2020","journal-title":"J Intern Med"},{"issue":"17","key":"10.1016\/j.gastha.2026.100992_bib54","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.3748\/wjg.v20.i17.4987","article-title":"NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis","volume":"20","author":"Fleischman","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gastha.2026.100992_bib55","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/oby.23960","article-title":"Noninvasive tests to identify liver fibrosis in metabolic dysfunction-associated steatotic liver disease are affected by race","volume":"32","author":"Bril","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.gastha.2026.100992_bib56","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000165","article-title":"Accuracy of noninvasive fibrosis scoring systems in African American and white patients with nonalcoholic fatty liver disease","volume":"11","author":"Marella","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"10.1016\/j.gastha.2026.100992_bib57","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/HEP.0000000000001243","article-title":"Prevalence and predictors of cirrhosis and portal hypertension in the United States","volume":"82","author":"Younossi","year":"2025","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.gastha.2026.100992_bib58","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/jama.2019.19365","article-title":"Prevalence of diabetes by race and ethnicity in the United States, 2011-2016","volume":"322","author":"Cheng","year":"2019","journal-title":"JAMA"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326001135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326001135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:23:03Z","timestamp":1783675383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326001135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326001135"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100992","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonlinear Association Between Metabolic Syndrome Severity and Advanced Fibrosis in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"100992"}}